SCANCELL HOLDINGS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.716 GBX | -3.80% |
|
-3.80% | -7.47% |
| Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
| Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 105M | - | - | - | - | - | |
| 62.59B | - | |||||
| 41.18B | ||||||
| 40.29B | ||||||
| 27.9B | ||||||
| 26.21B |
